Valuation: AbbVie

Market Cap 470B 403B 378B 345B 652B 44,809B 655B 4,471B 1,736B 22,599B 1,763B 1,725B 74,811B P/E 2026 *
33.6x
P/E 2027 * 24.8x
Enterprise Value 530B 455B 427B 390B 736B 50,580B 739B 5,046B 1,960B 25,510B 1,991B 1,947B 84,446B EV / Sales 2026 *
7.84x
EV / Sales 2027 * 7.09x
Free-Float
95.71%
Yield 2026 *
2.61%
Yield 2027 * 2.74%
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 470B
-3.59%-2.96%+71.06%+114.83% 1,100B
-1.15%-0.41%+51.34%+62.41% 658B
-1.09%+1.54%+26.67%+79.22% 470B
-1.47%+2.05%+41.71%+42.09% 372B
-0.90%+1.29%+25.62%+41.75% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.43%+3.54%+52.65%+71.75% 239B
-0.93%+2.90%-16.98%-52.28% 213B
-0.46%+3.24%+29.73%+92.67% 184B
Average -1.43%+3.01%+31.65%+51.74% 422.54B
Weighted average by Cap. -1.30%+2.21%+42.86%+68.24%

Financials

2026 *2027 *
Net sales 67.58B 57.99B 54.41B 49.71B 93.78B 6,448B 94.18B 643B 250B 3,252B 254B 248B 10,765B 73.52B 63.08B 59.19B 54.08B 102B 7,014B 102B 700B 272B 3,537B 276B 270B 11,710B
Net income 13.86B 11.89B 11.16B 10.2B 19.23B 1,322B 19.32B 132B 51.24B 667B 52.04B 50.91B 2,208B 18.91B 16.23B 15.23B 13.91B 26.25B 1,804B 26.36B 180B 69.91B 910B 71.01B 69.47B 3,013B
Net Debt 60.49B 51.9B 48.7B 44.49B 83.94B 5,771B 84.3B 576B 224B 2,911B 227B 222B 9,635B 51.66B 44.33B 41.59B 38B 71.69B 4,929B 71.99B 492B 191B 2,486B 194B 190B 8,229B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA